Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-28T18:20:10.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T00:16:31.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a new version of a clinical trial study on pembrolizumab and eribulin for HR-positive/HER2-negative metastatic breast cancer, with significant changes in the study description and investigator details.
    Difference
    44%
    Check dated 2025-04-22T18:12:58.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 19, 2025.
    Difference
    0.4%
    Check dated 2025-04-08T09:18:58.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The page has updated its version information from v2.14.2 to v2.14.3 and has changed the dates associated with the results and last update from February 19, 2025, to March 25, 2025.
    Difference
    0.3%
    Check dated 2025-04-01T05:45:01.000Z thumbnail image
  8. Check
    97 days ago
    Change Detected
    Summary
    The webpage has been updated to include new clinical trial results regarding the efficacy of Pembrolizumab in combination with Eribulin, detailing various metrics such as overall survival and progression-free survival in patients with PD-L1 positive tumors. Additionally, several outdated results and references have been removed.
    Difference
    21%
    Check dated 2025-02-24T09:54:55.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.